Enovis Corporation: Arvis Is Disrupting The Health Care Industry (NYSE:ENOV)
· seekingalpha.com
Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Click to read.
Health care is one of the most heavily funded markets in the world, both by corporations and the government. While still heavily funded, the industry suffers fr...